Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nefopam→

Nefopam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
13669-70-0
Molecular formula
C17H19NO
Molecular weight
253.34 g/mol
Drug class
Centrally acting non-opioid analgesicbenzoxazocine derivative
Mechanism of action
The precise mechanism is not fully established. Nefopam inhibits reuptake of serotonin, noradrenaline and dopamine and also modulates neuronal sodium and calcium channels, reducing central nociceptive transmission. It does not act through opioid receptors and does not produce the typical opioid respiratory-depressant mechanism.
Indications / reported uses
  • Relief of acute and chronic pain, including postoperative, dental, musculoskeletal, traumatic and cancer pain, according to the authorised product label.

Sources: https://www.medicines.org.uk/emc/product/15926/smpc · https://www.medicines.org.uk/emc/product/11685/smpc · https://sps.nhs.uk/articles/use-of-nefopam-for-chronic-pain/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nefopam Environmental Risk Assessment (ERA) (the Nefopam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.